Clinical Trial

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-01-08; most recent amendment 2025-09-22.
Status change: Not Yet Recruiting → Recruiting 2025-04-23
Trial Details
NCT Number NCT06212076
Lead Sponsor Nanjing Immunophage Biotech Co., Ltd
Conditions Solid Tumor
Enrollment 60 participants
Start Date 2024-07-11
Primary Completion 2027-07-09 (estimated)
Study Completion 2027-07-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-24